About Inotrem
Inotrem is a company based in Paris (France) founded in 2013.. Inotrem has raised $122.46 million across 7 funding rounds from investors including Bpifrance, Edmond de Rothschild and Kreos Capital. Inotrem offers products and services including Nangibotide and Monoclonal Antibodies. Inotrem operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and AskBio, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Inotrem S.A
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$122.46 M (USD)
in 7 rounds
-
Latest Funding Round
-
Investors
Bpifrance
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inotrem
Inotrem offers a comprehensive portfolio of products and services, including Nangibotide and Monoclonal Antibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats septic shock and COVID-19 through immunomodulation.
Targets chronic inflammatory diseases via TREM-1 pathway.
Unlock access to complete
Unlock access to complete
Funding Insights of Inotrem
Inotrem has successfully raised a total of $122.46M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Last Round
-
First Round
First Round
(13 Mar 2014)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Grant - Inotrem | Valuation |
investors |
|
| Dec, 2022 | Amount | Grant - Inotrem | Valuation |
investors |
|
| Feb, 2020 | Amount | Debt – Conventional - Inotrem | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inotrem
Inotrem has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Edmond de Rothschild and Kreos Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt is provided to growth-stage companies across multiple sectors.
|
Founded Year | Domain | Location | |
|
Risk capital is provided to life sciences entrepreneurs.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inotrem
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inotrem
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inotrem Comparisons
Competitors of Inotrem
Inotrem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and AskBio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inotrem
Frequently Asked Questions about Inotrem
When was Inotrem founded?
Inotrem was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Inotrem located?
Inotrem is headquartered in Paris, France.
Who is the current CEO of Inotrem?
Sven Zimmermann is the current CEO of Inotrem.
Is Inotrem a funded company?
Inotrem is a funded company, having raised a total of $122.46M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $15.28M, raised on Mar 13, 2014.
What does Inotrem do?
Inotrem was founded in 2013 in Paris, France, and operates in the biotechnology sector. Peptide-based drugs targeting the TREM-1 pathway are developed by the company for conditions such as septic shock and acute myocardial infarction. The lead candidate, Motrem, functions as a TREM-1 inhibitor through its role as a decoy receptor. This 12-amino-acid peptide is currently in phase I clinical trials.
Who are the top competitors of Inotrem?
Inotrem's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Inotrem offer?
Inotrem offers Nangibotide and Monoclonal Antibodies.
Who are Inotrem's investors?
Inotrem has 13 investors. Key investors include Bpifrance, Edmond de Rothschild, Kreos Capital, Andera Partners, and Crohn's & Colitis Foundation.